MRI影像特征评估不可切除肝细胞癌TACE联合靶向免疫治疗疗效与预后
回顾性纳入134例不可切除肝细胞癌患者,基线MRI后接受TACE联合靶向免疫治疗,随机分为训练组93例和验证组41例。LI-RADS的LR-TIV和腹水是治疗反应的独立预测因素,预测模型训练组AUC为0.692、验证组AUC为0.839;mRECIST客观缓解、介入次数和强化假包膜是PFS独立预测因素,mRECIST客观缓解、非环状动脉期高强化、瘤内出血和腹水与OS显著相关。
要点
- 基线MRI的LR-TIV和腹水是TACE联合靶向免疫治疗客观反应的独立预测因素。
- 预测模型训练组AUC 0.692、验证组AUC 0.839,列线图有助个体化评估。
- 强化假包膜是PFS独立预测因素,非环状动脉期高强化和瘤内出血与OS显著相关。
核心结论
- 治疗前LI-RADS MRI特征,尤其是LR-TIV和非环状动脉期高强化,结合临床变量,可为接受TTI的uHCC患者提供有价值的预后和预测信息;这些模型可能支持个体化治疗策略并辅助临床决策。
研究设计与样本
- 回顾性研究,纳入134例不可切除肝细胞癌患者,基线MRI后接受TACE联合靶向免疫治疗,随机分为训练组93例和验证组41例,以mRECIST标准评估治疗反应。
关键影像表现/征象
- LI-RADS肿瘤侵犯静脉(LR-TIV)和腹水是治疗反应的独立预测因素。
- 强化假包膜是PFS的独立预测因素。
- 非环状动脉期高强化和瘤内出血与OS显著相关。
诊断标准与关键数值
- 治疗反应预测模型AUC:训练组0.692,验证组0.839。
- mRECIST客观缓解、介入操作次数和强化假包膜是PFS的独立预测因素。
- mRECIST客观缓解、非环状动脉期高强化、瘤内出血和腹水与OS显著相关。
临床应用与阅片要点
- 阅片时可关注基线MRI的LR-TIV、腹水、强化假包膜、非环状动脉期高强化和瘤内出血等LI-RADS特征。
- 这些影像特征结合临床变量构建的列线图可能辅助个体化治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To identify significant MRI features associated with the efficacy and prognosis of TACE Combined with Targeted therapy and Immunotherapy (TTI) in patients with unresectable Hepatocellular Carcinoma(uHCC) and to assess the distribution of LI-RADS category assignments.
MATERIALS AND METHODS: This retrospective study included 134 uHCC patients who underwent baseline MRI prior to TTI. Patients were randomly divided into a training cohort (n = 93) and a validation cohort (n = 41). Treatment response was evaluated using mRECIST criteria. Multivariate logistic regression was performed to identify predictors of objective response. Cox regression models were used to identify prognostic factors for progression-free survival (PFS) and overall survival (OS). Nomograms were constructed and evaluated via receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA).
RESULTS: LI-RADS tumor in vein (LR-TIV) and ascites were independent predictors of treatment response. The predictive model achieved an area under the curve (AUC) of 0.692 (training) and 0.839 (validation). Multivariate Cox analysis identified objective response according to mRECIST, number of interventional procedures, and enhancing pseudocapsule as independent predictors of PFS, while OR-mRECIST, nonrim arterial phase hyperenhancement (APHE), intratumoral hemorrhage, and ascites were significantly associated with OS. The models demonstrated robust risk stratification and clinical utility.
CONCLUSION: Pre-treatment LI-RADS MRI features, particularly LR-TIV and nonrim APHE, combined with clinical variables, provide valuable prognostic and predictive information in uHCC patients undergoing TTI. These models may support individualized treatment strategies and inform clinical decision-making.
引用
- Yanfen L, Lixun C, Langlang T, et al. MRI imaging features for evaluating the efficacy and prognosis of TACE combined with targeted immunotherapy in unresectable hepatocellular carcinoma. Eur J Radiol. 2025. PMID: 40680471. doi:10.1016/j.ejrad.2025.112296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。